Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches

Listen Now

Topics Covered

• Overview of Diffuse Large B-Cell Lymphoma (DLBCL), in the Context of COVID, Omicron & Seasonal Flu
• Staging, Grading & Current Standard of Care
• Treatment Options for Relapsed Refractory DLBCL
• Bispecific Antibodies for Relapsed Refractory DLBCL
• Understanding How Bispecific Antibodies Work in the Treatment of Relapsed Refractory DLBCL
• New and Emerging Treatment Approaches
• The Role of Clinical Trials
• How Research Contributes to Treatment Choices
• Tips to Manage Side Effects, Symptoms, Discomfort & Pain
• Talking with Your Health Care Team about Quality-of-Life Concerns
• Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, Prepared List of Questions & Discussion of OpenNotes
• Questions for Our Panel of Experts

Our Panel of Experts

David J. Straus, MD

Hematology Oncologist, New York Cancer and Blood Specialists, Professor of Clinical Medicine, Weill Cornell Medical College

Adolfo Enrique Diaz, MD, MSc

Associate Professor, Department of Medicine, Division of Hematology-Oncology, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center

Belita Cowan, MA

President, Lymphoma Foundation of America®

Carolyn Messner, DSW, BCD, FAPOS, FAOSW

Senior Director of Education and Training, CancerCare

Brochure

You can download the brochure for this workshop

Workshop Date

This workshop was originally recorded on June 29, 2023.